Research programme: microRNA therapeutics - miRagen Therapeutics

Drug Profile

Research programme: microRNA therapeutics - miRagen Therapeutics

Alternative Names: AntimiR-15; AntimiR-155; AntimiR-208; AntimiRNA-15; LNA antimiR; MGN 7455; MGN-4893; mimics of the microRNA-183/96/182 - miRagen Therapeutics; miR-143/145; miR-15/195; miR-206; miR-208; miR-208/499; miR-29; miR-499; miR-92/126; miR-92a; MIRG-9103; miRNA-145 inhibitor; MRG-107

Latest Information Update: 08 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Servier; University of Glasgow; University of Texas Southwestern Medical Center
  • Class Cardiovascular therapies; Eye disorder therapies; MicroRNAs; Neuroprotectants
  • Mechanism of Action MicroRNA inhibitors; MIRN145-microRNA-inhibitors; RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Cardiovascular disorders; Heart failure; Hypertrophic cardiomyopathy; Ischaemia; Postmyocardial infarction; Retinal disorders
  • Discontinued Coronary artery restenosis; Fibrosis; Polycythaemia vera; Pulmonary arterial hypertension

Most Recent Events

  • 02 May 2018 Preclinical trials in Retinal disorders in USA (Parenteral) before May 2018
  • 14 Mar 2018 miRagen plans a phase I safety and tolerability trial in Healthy volunteers (Intradermal) in the first half of 2018
  • 24 Jan 2018 Preclinical development for Heart failure and Postmyocardial infarction is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top